Acquisition by Justin Burgess of 20000 shares of Dynavax Technologies at 11.7 subject to Rule 16b-3
| DVAX Stock | USD 13.01 0.03 0.23% |
Slightly above 53% of Dynavax Technologies' investor base is interested to short. The analysis of the overall investor sentiment regarding Dynavax Technologies suggests that many traders are impartial. Dynavax Technologies' investing sentiment can be driven by a variety of factors including economic data, Dynavax Technologies' earnings reports, geopolitical events, and overall market trends.
Dynavax |
Filed transaction by Dynavax Technologies Officer Vp Finance Cao. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Dynavax Technologies Fundamental Analysis
We analyze Dynavax Technologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dynavax Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dynavax Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Dynavax Technologies is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Dynavax Technologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dynavax Technologies stock to make a market-neutral strategy. Peer analysis of Dynavax Technologies could also be used in its relative valuation, which is a method of valuing Dynavax Technologies by comparing valuation metrics with similar companies.
Peers
Dynavax Technologies Related Equities
| EBS | Emergent Biosolutions | 2.87 | ||||
| DRRX | Durect | 2.41 | ||||
| NBIX | Neurocrine Biosciences | 1.73 | ||||
| ALKS | Alkermes Plc | 1.11 | ||||
| PCRX | Pacira BioSciences, | 0.81 | ||||
| ANIP | ANI Pharmaceuticals | 0.35 | ||||
| LNTH | Lantheus Holdings | 0.28 | ||||
| COLL | Collegium Pharmaceutical | 0.28 | ||||
| ITCI | Intracellular | 0.02 | ||||
| AMPH | Amphastar | 0.14 | ||||
| AQST | Aquestive Therapeutics | 0.65 | ||||
| IRWD | Ironwood Pharmaceuticals | 2.11 |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.